title: Quality of life of patients with end-stage peritoneal metastasis treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC).
abstract: BACKGROUND
  Quality of Life (QoL) plays an important role in patients with peritoneal metastasis and is deteriorating continuously until death. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) is an innovative palliative treatment of peritoneal metastasis. We present the first QoL results under PIPAC therapy.
  
  
  METHODS
  Retrospective analysis of QLQ30 questionnaire results during repeated courses of PIPAC applications in palliative patients with pretreated peritoneal metastasis.
  
  
  RESULTS
  91 patients (M:F = 40:51, median age 64 (34-77) years) with 158 PIPAC applications were analyzed. 86% patients had previously received systemic chemotherapy. Peritoneal metastasis was advanced (Peritoneal Carcinomatosis Index I = 16 ± 10). At admission, only moderate impairment of functioning (62-83%) and symptom scores (17-47%) was observed. 48 patients received at least 2 PIPAC every 6 weeks. After PIPAC # 1, the global physical score deteriorated slightly (from 82% to 75%), but improved after PIPAC # 2 (up to 89%). Gastrointestinal symptoms (nausea/vomiting, constipation, diarrhoea, anorexia) remained stable under PIPAC therapy.
  
  
  CONCLUSIONS
  Quality of life was relatively high in this group of patients with advanced, pretreated peritoneal metastasis, explaining their wish for further therapy. Functioning scores and disease-related symptoms were not altered for at least 3 months in the patients able to receive repeated PIPAC. Except for a transient moderate increase of pain scores, PIPAC did not cause therapy-related QoL deterioration, especially no gastrointestinal symptoms.
authors.affiliation: Dept. of Surgery, University of Magdeburg, Germany.
authors.forename: K
authors.initials: K
authors.lastname: Odendahl
authors.affiliation: Dept. of Surgery, Ruhr-University Bochum, Bochum, Germany.
authors.forename: W
authors.initials: W
authors.lastname: Solass
authors.affiliation: Dept. of Surgery, Ruhr-University Bochum, Bochum, Germany.
authors.forename: C
authors.initials: C
authors.lastname: Demtröder
authors.affiliation: Dept. of Surgery, Ruhr-University Bochum, Bochum, Germany.
authors.forename: U
authors.initials: U
authors.lastname: Giger-Pabst
authors.affiliation: Dept. of Surgery, Ruhr-University Bochum, Bochum, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Zieren
authors.affiliation: Gynaecology and Obstetrics, Ruhr-University Bochum, Bochum, Germany.
authors.forename: C
authors.initials: C
authors.lastname: Tempfer
authors.affiliation: Dept. of Surgery, University of Magdeburg, Germany; Dept. of Surgery, Ruhr-University Bochum, Bochum, Germany. Electronic address: marc.reymond@elisabethgruppe.de.
authors.forename: M A
authors.initials: MA
authors.lastname: Reymond
mesh_terms: D000328:Adult; D000336:Aerosols / Q000627:therapeutic use*; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy* / Q000556:secondary; D015331:Cohort Studies; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000473:pathology*; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D008654:Mesothelioma / Q000188:drug therapy*; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000473:pathology*; D000077150:Oxaliplatin; D010166:Palliative Care; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000556:secondary; D011788:Quality of Life; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000336:Aerosols; D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D004317:Doxorubicin
keywords: Chemotherapy administration; Cisplatin; Colorectal cancer; Doxorubicin; Gastric cancer; Ovarian cancer; Oxaliplatin; Peritoneal metastasis; Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC); Quality of life